论文部分内容阅读
资料来源:Medscape发布日期:2011.9.21一项II期临床研究表明,三重血管激酶抑制剂BIBF 1120可以提高复发性卵巢癌化疗后患者无进展生存期。Dr.Jonathan A及其同事注意到晚期卵巢癌患者通常对化疗有很好的治疗反应。很多妇女接受了多
Source: Medscape Release Date: 2011.9.21 A Phase II clinical study showed that triple vessel kinase inhibitor BIBF 1120 can improve progression-free survival in patients with recurrent ovarian cancer after chemotherapy. Dr. Jonathan A and colleagues note that patients with advanced ovarian cancer usually have a good response to chemotherapy. Many women have accepted more